<DOC>
	<DOCNO>NCT02173288</DOCNO>
	<brief_summary>The development ascites natural history cirrhosis herald worsen prognosis 50 % survival 2 year , deteriorate 30-50 % 1 year ascites become refractory medical therapy . Hemodynamic alteration relation neurohumoral system essential pathophysiology ascites formation . The theory best explain ascites formation sodium retention cirrhotics portal hypertension lead splanchnic arterial vasodilatation lead underfilling arterial circulation sense arterial cardiopulmonary receptor lead sympathetic nervous system activation activation anti-natriuretic factor ( RAAS arginine vasopressin ) , result sodium water retention . The therapeutic option available patient refractory ascites serial therapeutic paracentesis , liver transplantation transjugular intrahepatic portosystemic shunts.Vasopressin V2 receptor antagonist antagonize antidiuretic effect vasopressin V2 receptor locate renal collecting duct , increase free water clearance , thus may helpful mobilize excess water condition associate water retention include cirrhosis . The use V2 receptor antagonist cirrhosis ascites show safe efficacious . Midodrine , alpha adreno receptor agonist cause splanchnic vasoconstriction use hepatorenal syndrome ( HRS ) control ascites patient refractory recurrent ascites . It possible vasoconstrictor aquaretics ( V2 receptor antagonist ) act different site combination may reverse pathogenic event result refractory recurrent ascites.There report use combination midodrine tolvaptan patient cirrhosis ascites . Therefore , plan study role midodrine , tolvaptan combination systemic hemodynamics , renal function control ascites patient cirrhosis refractory recurrent ascites .</brief_summary>
	<brief_title>Role Midodrine Tolvaptan Patients With Cirrhosis With Refractory Recurrent Ascites</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Ascites</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Furosemide</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<mesh_term>Midodrine</mesh_term>
	<criteria>60 consecutive patient cirrhosis refractory recurrent ascites stable renal function ( creatinine level &lt; 1.5mg/dl least 7 day ) . Presence gastrointestinal bleeding , HRS , hepatic encephalopathy grade 2 high infection within 1 month precede study study , presence diabetes , intrinsic renal cardiovascular disease arterial hypertension history physical examination , abnormal urine analysis , chest radiograph electrocardiogram , presence hepatocellular carcinoma portal vein thrombosis treatment drug know effect systemic renal hemodynamics within 7 day inclusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>